Star Metro - Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

SAN FRANCISCO, CA / ACCESS Newswire / April 15, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar" or the "Company") family company Napo Pharmaceuticals ("Napo") today announced that the late-breaker abstract Napo submitted to MASCC on additional significant results in adult breast cancer patients from the OnTarget study has been accepted for presentation as an oral rapid e-poster at MASCC's June 26-28, 2025 Annual Meeting in Seattle, Washington. The authors include Pravin Chaturvedi, PhD, who is Jaguar's Chief Scientific Officer and Chair of Napo's Scientific Advisory Board, as well as leading oncologists and cancer patient advocates.

The abstract is titled OnTarget: Crofelemer or Placebo for the Prophylaxis of Diarrhea in Adults with Solid Tumors Initiating Targeted Therapy ± Chemotherapy (Tt/C)

"We're very pleased about the acceptance by MASCC of this new abstract, which describes the proportion of breast cancer patients who were continuous responders for the entire 3-month period of the OnTarget trial compared to breast cancer patients in the placebo arm of the study," said Lisa Conte, Jaguar's president and CEO.

"As a cancer patient, having options to manage the side effects of life saving drugs is very important. I believe the published results of crofelemer for the prophylaxis of cancer therapy-related are very exciting and compelling," said Dr. Kelly Shanahan, a former clinician and a metastatic breast cancer patient who serves on Napo's Scientific Advisory Board (SAB).

As announced, the U.S. Food and Drug Administration (FDA) has granted Napo a Type C Meeting in the second quarter of 2025 to discuss the responder analysis in the prespecified subgroup of patients with breast cancer for crofelemer in Napo's Phase 3 OnTarget trial. Patients with breast cancer accounted for 183 of the 287 participants in this unprecedented prophylactic clinical trial recently conducted by Napo for diarrhea in adults with solid tumors receiving targeted therapy with or without standard chemotherapy. The American Cancer Society expects 316,950 new cases of breast cancer diagnosed in women in the US in 2025,¹ and it's estimated that there were 4 million US women with a history of invasive breast cancer in 2022.²

"Diarrhea is a common side effect of targeted cancer therapies and can lead to dose changes, treatment delays, or cessation of treatment altogether, all of which can impact patient outcomes. We are very happy to have been granted a meeting with the FDA to review the positive OnTarget results in breast cancer patients and our goal is to discuss the most efficient pathways to make crofelemer - our novel, oral plant-based prescription medicine - available to this patient population for cancer therapy-related diarrhea (CTD)," said Conte.

Members of Napo's SAB are expected to join Jaguar representatives at the FDA meeting in the second quarter of 2025.

As previously announced, the initial top line results from the OnTarget study showed that the multicenter, double-blind, placebo-controlled pivotal clinical trial did not meet its primary endpoint for the prespecified analysis of all tumor types. The subgroup analysis in adult breast cancer patients indicates that crofelemer achieved significant results in this subgroup.

Napo today also announced that a second late-breaker abstract, related to the results of a recent Napo-sponsored screening survey of cancer patients about oral mucositis and a follow-up focus group, has also been accepted for presentation at MASCC's 2025 Annual Meeting. The abstract is titled Beyond the Pain: Patient Insights on Oral Mucositis in Cancer Treatment.

"Oral mucositis is a common, painful, and life-altering side effect of cancer treatment, frequently disrupting eating, speaking, sleeping, and social interactions. Capturing real-world patient experiences and insights can help to identify patient priorities and co-create solutions to support prevention and management of oral mucositis and enhance quality of life," said Stacey Tinianov, 11-year cancer survivor and founder of Advocates for Collaborative Education who serves on Napo's SAB. "I am delighted and honored that the results of the screening survey and focus group will be presented at MASCC's Annual Meeting this June."

Ms. Tinianov coordinated the screening survey and focus group in conjunction with cancer patients who serve as Ambassadors for Napo's ongoing Make Cancer Less Shitty (MCLS) patient advocacy program. The goal of the MCLS program is to drive awareness of cancer supportive care gaps and needs, bring together patients, advocates, researchers, and clinicians, and, most importantly, to amplify the voice of patients about the importance of supportive care.

"Oral mucositis has impacted my daily life constantly since 2016. Without proper supportive care, I have raw mouth sores and ulcerations from my gums and lips all the way down my throat. When severe, it impacts what I am able to eat, how I'm able to eat, and sometimes my ability to talk. The pain and irritation from oral mucositis affects my sleep and my self-confidence," said JJ Singleton, a metastatic colon cancer survivor and an Ambassador for Napo's MCLS patient advocacy program.

MASCC is an international, interdisciplinary organization dedicated to the practice, education and research of supportive care in cancer. The organization's mission is to continually improve the supportive care of people with cancer - from diagnosis through to survival or end-of-life care.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi^® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Napo will meet with the FDA in the second quarter of 2025 to discuss the results of the OnTarget study in breast cancer patients and potential pathways to bring crofelemer to this patient population as efficiently as possible for treatment of CTD, and the expectation that two Napo abstracts will be presented at MASCC's 2025 Annual Meeting. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

¹ Cancer Facts & Figures 2025, American Cancer Society

² Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022:1-23

Contact:

[email protected]

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

O.Lessard--SMC